市場調查報告書
商品編碼
1466126
細胞治療技術市場:按產品、製程、細胞類型和最終用戶 - 2024-2030 年全球預測Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Process (Cell Preservation, Distribution, & Handling, Cell Processing, Process Monitoring & Quality Control), Cell Type, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年細胞治療技術市場規模為194.8億美元,預計2024年將達223.1億美元,2030年將達506.9億美元,複合年成長率為14.63%。
細胞治療技術市場包括用於治療目的的細胞療法的研究、開發、生產和應用的產品、服務和技術。這包括廣泛的產品,例如消耗品(試劑、酵素、培養基)、設備(培養箱、離心機)和服務(細胞療法製造)。該領域主要由再生醫學和免疫療法的進步推動,再生醫學和免疫療法的重點是修復和替換受損的組織和細胞,以治療各種疾病和病症。細胞治療技術應用於多個領域,包括腫瘤學、心血管疾病治療、整形外科治療、自體免疫疾病管理、遺傳性遺傳疾病矯正等。癌症、糖尿病和心血管疾病等慢性疾病的全球負擔日益增加,加速了對創新治療方法的需求。此外,政府機構和私人投資者的有利資金籌措方案正在增加對細胞療法開發相關研究活動的投資。然而,細胞療法的開發和生產通常需要複雜的步驟,導致相關成本高昂,並限制了可負擔性和可用性。技術純熟勞工的短缺會影響業界的進步速度。為了克服這些挑戰,生物製藥公司和研究機構之間的策略聯盟正在迅速擴大。該行業可以透過利用人工智慧 (AI) 和機器學習 (ML) 來最佳化流程、確定細胞治療的新標靶以及利用 3D 生物列印來進一步擴大其影響範圍。
主要市場統計 | |
---|---|
基準年[2023] | 194.8億美元 |
預測年份 [2024] | 223.1億美元 |
預測年份 [2030] | 506.9億美元 |
複合年成長率(%) | 14.63% |
產品巨量資料分析工具的出現推動了細胞治療軟體工具的採用
耗材是細胞治療各階段所需的關鍵組件,包括細胞分離、擴增、分化和儲存。主要消耗品包括試劑、培養基、血清、生長因子和維持最佳細胞生長條件所需的其他補充品。細胞治療技術中使用的設備包括在將細胞施用給患者之前用於分離、精製、擴增、分化和基因修飾細胞的設備。此類別包括反應器(一次性或可重複使用)、離心機(用於根據密度分離細胞)和流式細胞儀(用於識別不同類型的細胞)。細胞治療耗材和設備使科學家能夠在培養物中培養新細胞,用於藥物開發目的。軟體解決方案對於有效管理、分析和解釋細胞治療過程中產生的資料至關重要。這些軟體工具有助於監控品管參數、分析資料和預測治療結果。
過程細胞保存技術的進展
細胞保存對於在儲存和運輸過程中維持細胞活力和功能至關重要。保存方法(冷凍保存、玻璃化等)和培養基選擇根據細胞類型和目的而變化。細胞加工涉及從骨髓和脂肪組織等各種來源分離、修飾和富集治療細胞。此步驟對於實現所需的治療效果同時最大限度地減少移植後副作用至關重要。過程監控可確保在整個製造過程中保持關鍵的品質屬性,以滿足細胞治療方法的監管要求。品管對於評估最終治療產品並確保其安全性、有效性和純度至關重要。
細胞類型 擴大人類細胞在細胞和基因治療的用途
動物細胞廣泛應用於多種研究領域,包括藥物發現、疾病建模、毒理學研究和基礎科學研究。動物細胞是研究細胞過程和理解複雜生物系統的寶貴工具。此外,動物細胞在生產治療藥物重組蛋白的生物過程中扮演重要角色。由於幹細胞研究和再生醫學的進步,人類細胞在治療中的使用顯著增加。人源細胞已成為個人化醫療方法的重要工具,透過根據其獨特的基因組成針對特定的患者特徵來治療和預防疾病。
政府鼓勵對最終用戶研究機構投資的舉措
在醫療保健和生命科學領域,個人化醫療、再生醫學以及改善患者治療效果的持續努力等因素正在推動對細胞治療技術的需求。這些技術包括用於分離、擴增、分析、儲存和運輸細胞的複雜設備和消耗品。基於醫療保健和生命科學機構需求的偏好從臨床級試劑到高效的細胞培養系統,可促進細胞快速生長,同時保持高品質標準。該研究所主要致力於了解細胞過程、識別新的治療標靶以及開發利用細胞治療技術治療疾病的創新方法。他們的需求包括最先進的分析和數位工具,可以準確洞察各種條件下的細胞行為。
區域洞察
美國和加拿大是美洲細胞治療技術發展的主要貢獻者。這裡有完善的生物技術和製藥產業,許多研究機構都在促進該領域的創新。美國在細胞治療創新相關專利申請數量方面處於領先地位,這正在推動私人和公共機構的投資。此外,政府推動腫瘤學和遺傳疾病研究的措施和資金正在加速基因和細胞治療技術的發展。在歐洲,注重研發的歐盟國家在細胞治療技術市場中處於領先地位。多家歐洲生物技術公司在先進治療藥物(ATMP)的臨床試驗中取得了巨大成功。在亞太地區,中國、日本和印度是細胞治療技術成長最快的市場。中國已成為主要參與者,對專門從事細胞治療的生物技術公司進行了大量投資。中國的監管改革加快了臨床試驗的核准流程,並促進了細胞療法的快速商業化。日本在再生醫學研究方面的領先地位很大程度上得益於政府對該領域的積極支持。
FPNV定位矩陣
FPNV定位矩陣對於評估細胞治療技術市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對細胞治療技術市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.細胞治療技術市場的市場規模與預測是多少?
2.在細胞治療技術市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.細胞治療技術市場的技術趨勢與法規結構是什麼?
4.細胞治療技術市場主要廠商的市場佔有率為何?
5. 進入細胞治療技術市場的適當型態和策略手段是什麼?
[188 Pages Report] The Cell Therapy Technologies Market size was estimated at USD 19.48 billion in 2023 and expected to reach USD 22.31 billion in 2024, at a CAGR 14.63% to reach USD 50.69 billion by 2030.
The cell therapy technologies market encompasses the products, services, and techniques employed in the research, development, production, and application of cellular therapies for therapeutic purposes. This includes a wide range of products such as consumables (reagents, enzymes, media), equipment (incubators, centrifuges), and services (cell therapy manufacturing). The field is primarily driven by advancements in regenerative medicine and immunotherapies that focus on repairing or replacing damaged tissue or cells to treat various diseases and disorders. Cell therapy technologies find applications in multiple areas such as oncology, cardiovascular disease treatment, orthopedic treatments, autoimmune disorders management, and inherited genetic disorders correction. The increasing global burden of chronic diseases such cancer, diabetes and cardiovascular disorders has accelerated the demand for innovative therapies. Additionally, favorable funding scenarios from government agencies and private investors have led to increased investments in research activities related to cell therapy development. However, the development and production of cell therapies often require complex procedures, which result in high associated costs, limiting their affordability and accessibility. A dearth of skilled workers may affect the rate at which advancements are made within the industry. Strategic alliances among biopharmaceutical companies and research institutes are rapidly expanding to overcome such challenges. Leveraging artificial intelligence (AI) and machine learning (ML) to optimize processes or identify new targets for cellular therapies and utilization of 3D bioprinting can further expand the scope of the industry.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 19.48 billion |
Estimated Year [2024] | USD 22.31 billion |
Forecast Year [2030] | USD 50.69 billion |
CAGR (%) | 14.63% |
Product: The advent of big data analytics tools driving the adoption of software tools for cell therapies
Consumables are essential components required during the various stages of cell therapy procedures, such as cell isolation, expansion, differentiation, and preservation. Key consumables include reagents, media, sera, growth factors, and other supplements needed to maintain optimal cell growth conditions. Equipment used in cell therapy technologies includes devices for isolation, purification, expansion, differentiation, or genetic modification of cells before administering them to patients. This category comprises bioreactors (single-use or reusable), centrifuges (for separating cells based on density), and flow cytometers (for identifying different types of cells). Cell therapy consumables and equipment enable scientists to grow new cells in the culture media for the purpose of drug development. Software solutions are critical to the effective management, analysis, and interpretation of data generated during cell therapy procedures. These software tools assist in monitoring quality control parameters, data analysis, and predicting treatment outcomes.
Process: Advancements in cell preservation technologies
Cell preservation is vital for maintaining the viability and functionality of cells during storage and transportation. The selection of preservation methods (such as cryopreservation or vitrification) and media depends on the cell type and intended application. Cell processing involves the isolation, modification, and concentration of therapeutic cells from various sources, such as bone marrow or adipose tissue. This step is crucial for achieving desired therapeutic effects while minimizing adverse reactions post-transplantation. Process monitoring ensures that critical quality attributes are maintained throughout manufacturing processes to meet regulatory requirements for cell-based therapies. Quality control is critical for evaluating the final therapeutic product and ensuring its safety, efficacy, and purity.
Cell type: Rising utilization of human cells in cell and gene therapies
Animal cells are widely used in various research areas, including drug discovery, disease modeling, toxicology studies, and basic science research. They serve as valuable tools in studying cellular processes and understanding complex biological systems. Moreover, animal cells play a significant role in bioprocessing for the production of recombinant proteins for therapeutics. The use of human cells in therapy has increased significantly due to advancements in stem cell research and regenerative medicine. Human-derived cells have become essential tools for personalized medicine approaches that aim to treat or prevent diseases by targeting specific patient profiles based on their unique genetic makeup.
End user: Government initiatives to propel investments in research institutes
In the healthcare and life science sector, the need for cell therapy technologies has been increasing due to factors such as personalized medicine, regenerative medicine, and the ongoing drive to improve patient outcomes. These technologies include advanced equipment and consumables used in cell isolation, expansion, analysis, storage, and transportation. Need-based preferences for healthcare and life science organizations range from clinical-grade reagents to efficient cell culture systems that promote rapid cell growth while maintaining high-quality standards. Research institutes primarily focus on understanding cellular processes, identifying new therapeutic targets, and developing innovative approaches for disease treatment using cell therapy technologies. Their needs include cutting-edge analytical and digital tools that provide accurate insights into cellular behavior under various conditions.
Regional Insights
The United States and Canada are major contributors to the growth of cell therapy technologies in the Americas. The presence of established biotechnology and pharmaceutical industries, along with numerous research institutions, drives innovation in this sector. The U.S. leads in patents filed for cell therapy innovations, which encourages investments from private and public entities. Furthermore, government initiatives and funding to propel research for oncology and genetic diseases have accelerated the development of gene and cell therapy technologies. In Europe, the European Union (EU) countries lead the market for cell therapy technologies with a strong focus on research and development. Several European biotech firms have made significant progress in clinical trials for advanced therapeutic medicinal products (ATMPs). China, Japan, and India are fast-growing markets for cell therapy technologies within the Asia Pacific region. China has established itself as a major player due to its considerable investment in biotech companies focused on cellular therapies. Chinese regulatory reforms have expedited approval processes for clinical trials, enabling rapid commercialization of cell therapies. Japan leads in regenerative medicine research primarily because of its government's proactive support for the sector.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cell Therapy Technologies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell Therapy Technologies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cell Therapy Technologies Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Atara Biotherapeutics by FUJIFILM Corporation, Athersys, Inc., Becton, Dickinson and Company, Bluebird Bio, Inc., Bristol-Myers Squibb Company, Cellectis SA, Danaher Corporation, ElevateBio, Gamida Cell, GE Healthcare, Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Johnson & Johnson Services, Inc., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novartis AG, Sartorius AG, STEMCELL Technologies Inc., Takeda Pharmaceutical Company Limited, Tego Science, Terumo Bct, Inc., Thermo Fisher Scientific, Inc., and Vericel Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Cell Therapy Technologies Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell Therapy Technologies Market?
3. What are the technology trends and regulatory frameworks in the Cell Therapy Technologies Market?
4. What is the market share of the leading vendors in the Cell Therapy Technologies Market?
5. Which modes and strategic moves are suitable for entering the Cell Therapy Technologies Market?
TABLE 33